The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori.
Gastric cancer is one of the most important worldwide public health problems. Convincing epidemiologic and etiologic associations have been made between the development of gastric cancer and infection with Helicobacter pylori. H. pylori not only has adapted to survive within the harsh environment of the stomach but also is able to modulate and avoid endogenous immune responses. The design and creation of efficacious vaccine strategies against H. pylori requires an understanding of the complex interactions that make up mucosal immunity. An effective vaccine strategy against H. pylori has the potential to affect significantly on population health worldwide.
Chui
Stephen Y
SY
Duke University Medical Center, Box 2606, Durham, NC 27710, USA.
Clay
Timothy M
TM
Lyerly
H Kim
HK
Morse
Michael A
MA
D000230:Adenocarcinoma / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D000942:Antigens, Bacterial / Q000187:drug effects / Q000276:immunology*; D001426:Bacterial Proteins / Q000187:drug effects / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control; D016480:Helicobacter pylori / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D013274:Stomach Neoplasms / Q000209:etiology / Q000276:immunology / Q000517:prevention & control
D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D019496:Cancer Vaccines; C080866:cagA protein, Helicobacter pylori